Text Size

Acceptability of Depo-subQ in Uniject

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
United States Agency for International Development (USAID)
Program for Appropriate Technology in Health
Information provided by (Responsible Party):
FHI 360
ClinicalTrials.gov Identifier:
NCT01667276
First received: August 2, 2012
Last updated: March 5, 2013
Last verified: August 2012
History of Changes
  Purpose

This is an observational study to assess the experience of current depot medroxyprogesterone acetate (DMPA) intramuscular (IM) clients and providers when they try Depo-subQ in Uniject and offer recommendations for the introduction of this method.


Condition
Contraceptive Acceptability

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Acceptability of Depo-subQ in Uniject

Resource links provided by NLM:

MedlinePlus related topics: Birth Control
U.S. FDA Resources

Further study details as provided by FHI 360:

Primary Outcome Measures:
  • Measure the acceptability of Depo-subQ in Uniject among DMPA IM family planning clients; [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    percent of participants who declare they would select Depo-subQ in Uniject for their next injection if this drug product was available at three months with a 95% confidence interval per country

  • 2) Measure the acceptability of Depo-subQ in Uniject among family planning providers (both clinic-based and CHWs); [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    key themes will be identified from interview transcripts to summarize family planning providers' (clinic-based and CHWs) acceptability of Depo-subQ in Uniject and preference for administering Depo-subQ in Uniject relative to the typical DMPA intramuscular injection by county

  • Assess family planning providers' (clinic-based and CHWs) training materials. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    descriptive analyses (e.g., frequencies and means) of responses for quantitative questions and summaries providers' qualitative responses to open-ended questions from the post-training evaluation for each country


Secondary Outcome Measures:
  • 1) To qualitatively compare acceptability of Depo-subQ in Uniject among the two types of family planning providers—clinic-based and CHWs (Senegal only) [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    frequencies and summary statistics of acceptability data among family planning clients by asking participants to compare their experiences receiving Depo-subQ in Uniject to their experiences receiving the typical DMPA intramuscular injection by country

  • 2) To assess the safety of participants who receive Depo-subQ in Uniject during the study [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    frequencies of reported adverse events by country


Estimated Enrollment: 560
Study Start Date: July 2012
Estimated Study Completion Date: May 2013
Estimated Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Detailed Description:

This is an observational study to assess the experience of current depot medroxyprogesterone acetate (DMPA) intramuscular (IM) clients and providers when they try Depo-subQ in Uniject and offer recommendations for the introduction of this method.

A total of 560 participants will be enrolled in the study in the following groups:

360 participants (120 in Uganda and 240 in Senegal) who are current DMPA IM clients who seek re-injection of DMPA from either CHWs or clinic-based providers; and are 18-40 years of age; received their most recent DMPA injection no more than 13 weeks prior to enrollment in the study [16].

Up to 100 participants (50 in Uganda and 50 in Senegal) current DMPA IM clients who meet the inclusion/exclusion criteria but do not want to receive the injection with Depo-subQ in Uniject and are willing to complete a short questionnaire

80 CHWs (40 in Uganda and 40 in Senegal) and 20 clinic-based providers (from Senegal only) who are trained to give Depo-subQ in Uniject as part of this study

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

A total of 560 participants will be enrolled in the study in the following groups:

  • 360 participants (120 in Uganda and 240 in Senegal) who are current DMPA IM clients who seek re-injection of DMPA from either CHWs or clinic-based providers; and are 18-40 years of age; received their most recent DMPA injection no more than 13 weeks prior to enrollment in the study [16].
  • Up to 100 participants (50 in Uganda and 50 in Senegal) current DMPA IM clients who meet the inclusion/exclusion criteria but do not want to receive the injection with Depo-subQ in Uniject and are willing to complete a short questionnaire
  • 80 CHWs (40 in Uganda and 40 in Senegal) and 20 clinic-based providers (from Senegal only) who are trained to give Depo-subQ in Uniject as part of this study
Criteria

Inclusion Criteria:

  • Age 18-40
  • In general good health (the participant verbally reports she feels well)
  • Using DMPA continuously for at least six months prior to enrollment in the study (i.e., had at least two previous injections)
  • Received their most recent DMPA injection no more than 13 weeks prior to enrollment in the study at the study clinic or from a family planning provider involved in the study (Senegal only)
  • Received their most recent DMPA injection no more than 13 weeks prior to enrollment in the study from a family planning provider involved in the study (Uganda only)
  • Desires to be re-injected with DMPA
  • Willing to sign an informed consent document
  • Willing to provide contact information and be interviewed three months after enrollment.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01667276

Locations
Senegal
Ministry of Health Clinics
All Cities Where There Is A Clinic, Senegal
Uganda
Ministry of Health Clinics, Uganda
All Cities Where There Is A Clinic, Uganda
Sponsors and Collaborators
FHI 360
United States Agency for International Development (USAID)
Program for Appropriate Technology in Health
Investigators
Principal Investigator: Holly Burke, PhD, MPH FHI 360
Principal Investigator: Anthony Mbonye, MD, PhD Ministry of Health, Uganda
Principal Investigator: Bpcar M Daff, MD, PhD, MSc Division de la Sante de la Reproduction
  More Information

No publications provided

Responsible Party: FHI 360
ClinicalTrials.gov Identifier: NCT01667276     History of Changes
Other Study ID Numbers: 10196
Study First Received: August 2, 2012
Last Updated: March 5, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by FHI 360:
AE adverse event
AIDS acquired immunodeficiency syndrome
ALT (SGPT) alanine aminotransferase
ART antiretroviral therapy
AST (SGOT) aspartate aminotransferase
DCF data collection forms
DMC Data Monitoring Committee
FDA (U.S.) Food and Drug Administration
GCP Good Clinical Practice guidelines
HB sAg Hepatitis B surface antigen
ICH International Conference of Harmonisation
 IND Investigational New Drug Application
IRB Institutional Review Board
IU international units
mg milligram(s)
mm3 cubic millimeter(s)
PCR polymerase chain reaction
SAE serious adverse event
µg microgram
ULN upper limit of the normal range
WB Western Blot

ClinicalTrials.gov processed this record on May 16, 2013